BR9608255A - Sistema terapéutico transdérmico (stt) para a administração de testosterona - Google Patents

Sistema terapéutico transdérmico (stt) para a administração de testosterona

Info

Publication number
BR9608255A
BR9608255A BR9608255A BR9608255A BR9608255A BR 9608255 A BR9608255 A BR 9608255A BR 9608255 A BR9608255 A BR 9608255A BR 9608255 A BR9608255 A BR 9608255A BR 9608255 A BR9608255 A BR 9608255A
Authority
BR
Brazil
Prior art keywords
stt
therapeutic system
transdermal therapeutic
testosterone administration
testosterone
Prior art date
Application number
BR9608255A
Other languages
English (en)
Inventor
Daniel Bracher
Wilfried Fischer
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal Ag filed Critical Hexal Ag
Publication of BR9608255A publication Critical patent/BR9608255A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BR9608255A 1995-05-10 1996-05-10 Sistema terapéutico transdérmico (stt) para a administração de testosterona BR9608255A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19517145A DE19517145C2 (de) 1995-05-10 1995-05-10 Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron
PCT/EP1996/002013 WO1996035427A1 (de) 1995-05-10 1996-05-10 Transdermales therapeutisches system (tts) zur verabreichung von testosteron

Publications (1)

Publication Number Publication Date
BR9608255A true BR9608255A (pt) 1999-02-02

Family

ID=7761562

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9608255A BR9608255A (pt) 1995-05-10 1996-05-10 Sistema terapéutico transdérmico (stt) para a administração de testosterona

Country Status (17)

Country Link
EP (1) EP0825865B1 (pt)
JP (1) JPH11504643A (pt)
CN (1) CN1183723A (pt)
AT (1) ATE208200T1 (pt)
AU (1) AU702710B2 (pt)
BR (1) BR9608255A (pt)
CA (1) CA2220358A1 (pt)
CZ (1) CZ287678B6 (pt)
DE (2) DE19517145C2 (pt)
DK (1) DK0825865T3 (pt)
HU (1) HUP9801130A3 (pt)
NO (1) NO975140L (pt)
NZ (1) NZ308516A (pt)
PL (1) PL323145A1 (pt)
SK (1) SK149797A3 (pt)
WO (1) WO1996035427A1 (pt)
ZA (1) ZA963743B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024148A1 (en) * 1995-12-29 1997-07-10 Cygnus, Inc. Systems and methods for the transdermal administration of androgenic agents
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
ATE226816T1 (de) * 1996-07-03 2002-11-15 Alza Corp Vorrichtungen zur arzneistoffabgabe und herstellungsverfahren
DE19646050A1 (de) * 1996-11-08 1998-05-14 Labtec Gmbh Transdermales System mit einem speziellen Süßstoff zur Erhöhung der transdermalen Bioverfügbarkeit
US6174545B1 (en) 1997-07-01 2001-01-16 Alza Corporation Drug delivery devices and process of manufacture
ES2226394T3 (es) * 1998-05-22 2005-03-16 Novosis Ag Sistemas transdermales que contienen substancia activa que se libera de forma controlada en el tiempo.
FR2793689B1 (fr) * 1999-05-19 2001-08-24 Pf Medicament Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE602005020393D1 (de) 2004-06-01 2010-05-20 Hisamitsu Pharmaceutical Co Adhäsive Pflaster
NZ567056A (en) 2005-10-12 2012-02-24 Unimed Pharmaceuticals Llc Improved testosterone gel and method of use
FR2895679B1 (fr) * 2005-12-29 2012-06-08 Pf Medicament Stabilisation de testosterone au sein de dispositifs transdermiques
CN101480399B (zh) * 2008-09-25 2011-10-05 宋博 睾酮在制备治疗弱精子症的药物中的应用
DE102011012712A1 (de) 2011-03-01 2012-09-06 Frank Lehmann-Horn Verwendung von Aldosteron-Rezeptor-Antagonisten zur Behandlung von weiblicher sexueller Dysfunktion

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4286592A (en) * 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
GB8804164D0 (en) * 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
PT100502A (pt) * 1991-05-20 1993-08-31 Alza Corp Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
DK0644746T3 (da) * 1992-06-11 1999-12-20 Theratech Inc Anvendelse af glycerin til moderering af transdermal lægemiddelafgivelse
DE59409873D1 (de) * 1993-04-20 2001-10-25 Hexal Ag Wirkstoffpflaster
DE4313402A1 (de) * 1993-04-23 1994-10-27 Hexal Pharma Gmbh Transdermale Wirkstoffzubereitung
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women

Also Published As

Publication number Publication date
DE59608150D1 (de) 2001-12-13
CZ287678B6 (en) 2001-01-17
CN1183723A (zh) 1998-06-03
AU702710B2 (en) 1999-03-04
CA2220358A1 (en) 1996-11-14
JPH11504643A (ja) 1999-04-27
ZA963743B (en) 1996-11-18
NO975140D0 (no) 1997-11-07
EP0825865A1 (de) 1998-03-04
NZ308516A (en) 1999-05-28
DE19517145C2 (de) 2000-02-24
AU5805096A (en) 1996-11-29
SK149797A3 (en) 1998-05-06
DE19517145C1 (de) 1996-11-28
WO1996035427A1 (de) 1996-11-14
CZ351297A3 (cs) 1998-03-18
EP0825865B1 (de) 2001-11-07
ATE208200T1 (de) 2001-11-15
NO975140L (no) 1997-11-10
HUP9801130A3 (en) 2001-03-28
HUP9801130A2 (hu) 1998-08-28
DK0825865T3 (da) 2002-02-18
PL323145A1 (en) 1998-03-16

Similar Documents

Publication Publication Date Title
MX9207263A (es) Sistema para el suministro de una substancia activa para la liberacion sostenida.
IT1283102B1 (it) Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
PT1051217E (pt) Sistema de controlo osmotico de administracao de medicamento
ZA962536B (en) Pharmaceutical composition for transdermal administration.
MX9203422A (es) Compuestos farmacologicamente activos para el sistema nervioso central.
BR9608255A (pt) Sistema terapéutico transdérmico (stt) para a administração de testosterona
EP0934065A4 (en) PHARMACEUTICAL COMPOSITION
AU6995700A (en) Therapeutic system containing an active substance for the application on the skin which contains at least two polymerous layers
DE59408643D1 (de) Transdermale therapeutische systeme zur verabreichung von serotoninagonisten
ATE450254T1 (de) Schwimmende pharmazeutische zusammensetzung mit einer aktiven phase und einer inaktiven phase
ZA968905B (en) Transdermal therapeutic system (tts) for administering active substances for drug dependence or drug addiction
CY1105463T1 (el) Ελεγχομενη χορηγηση αντικαταθλιπτικων
DE69626544T2 (de) Arzneistoffe
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
CA2331414A1 (en) Transdermal therapeutic system for the administration of candesartan
IL96506A0 (en) Transdermal system for administering pharmaceutical compounds under ph control
ATE211383T1 (de) Topische aciclovir-zubereitung
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.
ZA966083B (en) Agent for transdermal administration containing esters of 13-ethyl-17ß-hydroxy-11-methylene-18,19-dinor-17Ó-pregn-4-en-20-yn-3-one.
ES2136965T3 (es) Derivados de 17-hidroxiiminoalquil y 17-hidroxiiminometilalquenil ciclopentanperhidrofenantreno activos sobre el sistema cardiovascular un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
FI970053A (fi) Transdermaalinen lääkeaineen antosysteemi
MX9203154A (es) Sistema terapeutico de liberacion regulada para formulaciones farmaceuticas liquidas.

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements